Search & Evaluation Late TA Lead, Senior Director (CVR)

Serve as the senior S&E leader within the TALT, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.​

Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.​

Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations​

Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.​

Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.​

Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.​

Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution​

Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.​

15+ years in biopharma with significant experience in clinical development, external innovation, or business development.​

Advanced degree required (MD, PhD, or equivalent).​

Deep clinical expertise in Immunology, Hematology, or Cardiovascular/Renal therapeutic areas.​

Proven track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.​

Strong understanding of regulatory pathways, market access, and competitive standards of care.​